An update on gene therapy for lysosomal storage disorders

References

• Fuller M, Meikle P, Hopwood J. Epidemiology of lysosomal storage diseases: an overview. In: Mehta A, Bec K, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006. Available from:  https://www.ncbi.nlm.nih.gov/books/NBK11586/
   Google Scholar
• Griffiths G, Hoflack B, Simons K, et al. The mannose 6-phosphate receptor and the biogenesis of lysosomes. Cell. 1988 Feb 12;52(3):329–341. PubMed PMID: 2964276
   PubMed Web of Science ®Google Scholar
• Coutinho MF, Prata MJ, Alves S. Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction. Mol Genet Metab. 2012 Apr;105(4):542–550. PubMed PMID: 22266136
   PubMed Web of Science ®Google Scholar
• Neufeld EF. The uptake of enzymes into lysosomes: an overview. Birth Defects Orig Artic Ser. 1980;16(1):77–84. PubMed PMID: 7448363
   PubMedGoogle Scholar
• Solomon M, Muro S. Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev. 2017 Sep 1;118:109–134. PubMed PMID: 28502768; PubMed Central PMCID: PMCPMC5828774.
   PubMed Web of Science ®Google Scholar
• Ohashi T. Enzyme replacement therapy for lysosomal storage diseases. Pediatr Endocrinol Rev. 2012 Oct;10(Suppl 1):26–34. PubMed PMID: 23330243
   PubMedGoogle Scholar
• Broomfield A, Jones SA, Hughes SM, et al. The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders. J Inherit Metab Dis. 2016 Jul;39(4):499–512. PubMed PMID: 26883220
   PubMed Web of Science ®Google Scholar
• Visigalli I, Delai S, Ferro F, et al. Preclinical testing of the safety and tolerability of lentiviral vector-mediated above-normal alpha-L-Iduronidase expression in murine and human hematopoietic cells using toxicology and biodistribution good laboratory practice studies. Hum Gene Ther. 2016 Oct;27(10):813–829. PubMed PMID: 27431943.
   PubMed Web of Science ®Google Scholar
• Kierdorf K, Katzmarski N, Haas CA, et al. Bone marrow cell recruitment to the brain in the absence of irradiation or parabiosis bias. PLoS One. 2013;8(3):e58544. PubMed PMID: 23526995; PubMed Central PMCID: PMCPMC3592806
   PubMed Web of Science ®Google Scholar
• Tolar J, Grewal SS, Bjoraker KJ, et al. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for hurler syndrome. Bone Marrow Transplant. 2008 Mar;41(6):531–535. PubMed PMID: 18037941.
   PubMed Web of Science ®Google Scholar
• Neufeld E, Muenzer J. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001.
   Google Scholar
• Hilgendorf I, Greinix H, Halter JP, et al. Long-term follow-up after allogeneic stem cell transplantation. Dtsch Arztebl Int. 2015 Jan 23;112(4):51–58. PubMed PMID: 25797423; PubMed Central PMCID: PMCPMC4335490.
   PubMed Web of Science ®Google Scholar
• Franco LM, Sun B, Yang X, et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther. 2005 Nov;12(5):876–884. PubMed PMID: 16005263.
   PubMed Web of Science ®Google Scholar
• van Til NP, Stok M, Aerts Kaya FS, et al. Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the pompe disease phenotype. Blood. 2010 Jul 1;115(26):5329–5337. PubMed PMID: 20385789.
   PubMed Web of Science ®Google Scholar
• Hagedorn C, Schnodt-Fuchs M, Boehme P, et al. S/MAR element facilitates episomal long-term persistence of adeno-associated virus vector genomes in proliferating cells. Hum Gene Ther. 2017 Dec;28(12):1169–1179. PubMed PMID: 28665147.
   PubMed Web of Science ®Google Scholar
• Ewert KK, Zidovska A, Ahmad A, et al. Cationic liposome-nucleic acid complexes for gene delivery and silencing: pathways and mechanisms for plasmid DNA and siRNA. Top Curr Chem. 2010;296:191–226. PubMed PMID: 21504103; PubMed Central PMCID: PMCPMC3867951
   PubMed Web of Science ®Google Scholar
• Budker V, Zhang G, Knechtle S, et al. Naked DNA delivered intraportally expresses efficiently in hepatocytes. Gene Ther. 1996 Jul;3(7):593–598. PubMed PMID: 8818646
   PubMed Web of Science ®Google Scholar
• Bharali DJ, Klejbor I, Stachowiak EK, et al. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11539–11544. PubMed PMID: 16051701; PubMed Central PMCID: PMCPMC1181239.
   PubMed Web of Science ®Google Scholar
• Roth TL, Puig-Saus C, Yu R, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018 Jul;559(7714):405–409. PubMed PMID: 29995861.
   PubMed Web of Science ®Google Scholar
• Latta-Mahieu M, Rolland M, Caillet C, et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther. 2002 Sep 1;13(13):1611–1620. PubMed PMID: 12228016.
   PubMed Web of Science ®Google Scholar
• Dupont JB, Tournaire B, Georger C, et al. Short-lived recombinant adeno-associated virus transgene expression in dystrophic muscle is associated with oxidative damage to transgene mRNA. Mol Ther Methods Clin Dev. 2015;2:15010. PubMed PMID: 26029721; PubMed Central PMCID: PMCPMC4445007
   PubMed Web of Science ®Google Scholar
• Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003 Sep–Oct;80(1–2):148–158. PubMed PMID: 14567964
   PubMed Web of Science ®Google Scholar
• Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther. 1996 Nov 10;7(17):2101–2112. PubMed PMID: 8934224.
   PubMed Web of Science ®Google Scholar
• Sumner-Jones SG, Davies LA, Varathalingam A, et al. Long-term persistence of gene expression from adeno-associated virus serotype 5 in the mouse airways. Gene Ther. 2006 Dec;13(24):1703–1713. PubMed PMID: 16855618.
   PubMed Web of Science ®Google Scholar
• Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology. 2013 Jun;120(6):1283–1291. PubMed PMID: 23474247; PubMed Central PMCID: PMCPMC3674112.
   PubMed Web of Science ®Google Scholar
• von Kalle C, Fehse B, Layh-Schmitt G, et al. Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable. Semin Hematol. 2004 Oct;41(4):303–318. PubMed PMID: 15508116
   PubMed Web of Science ®Google Scholar
• Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008 Sep;118(9):3143–3150. PubMed PMID: 18688286; PubMed Central PMCID: PMCPMC2496964.
   PubMed Web of Science ®Google Scholar
• Schroder AR, Shinn P, Chen H, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002 Aug 23;110(4):521–529. PubMed PMID: 12202041
   PubMed Web of Science ®Google Scholar
• Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998 Dec;72(12):9873–9880. PubMed PMID: 9811723; PubMed Central PMCID: PMCPMC110499
   PubMed Web of Science ®Google Scholar
• Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996 Apr 12;272(5259):263–267. PubMed PMID: 8602510
   PubMed Web of Science ®Google Scholar
• Biffi A. Hematopoietic stem cell gene therapy for storage disease: current and new indications. Mol Ther. 2017 May 3;25(5):1155–1162. PubMed PMID: 28389320; PubMed Central PMCID: PMCPMC5417839.
   PubMed Web of Science ®Google Scholar
• Tarnopolsky M, Katzberg H, Petrof BJ, et al. Pompe disease: diagnosis and management. evidence-based guidelines from a canadian expert panel. Can J Neurol Sci. 2016 Jul;43(4):472–485. PubMed PMID: 27055517.
   PubMed Web of Science ®Google Scholar
• Bascou N, DeRenzo A, Poe MD, et al. A prospective natural history study of Krabbe disease in a patient cohort with onset between 6 months and 3 years of life. Orphanet J Rare Dis. 2018 Aug 9;13(1):126. PubMed PMID: 30089515; PubMed Central PMCID: PMCPMC6083585.
   PubMedGoogle Scholar
• Vellodi A, Bembi B, de Villemeur TB, et al. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis. 2001 June;24(3):319–327. PubMed PMID: 11486896
   PubMed Web of Science ®Google Scholar
• Muller-Sieburg CE, Cho RH, Thoman M, et al. Deterministic regulation of hematopoietic stem cell self-renewal and differentiation. Blood. 2002 Aug 15;100(4):1302–1309. PubMed PMID: 12149211
   PubMed Web of Science ®Google Scholar
• Felfly H, Haddad GG. Hematopoietic stem cells: potential new applications for translational medicine. J Stem Cells. 2014;9(3):163–197. PubMed PMID: 25157450
   PubMedGoogle Scholar
• Gratwohl A, Baldomero H, Passweg J, et al. Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia. 2003 May;17(5):941–959. PubMed PMID: 12750709.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Gray D, Lomova A, et al. Hematopoietic stem cell gene therapy: progress and lessons learned. Cell Stem Cell. 2017 Nov 2;21(5):574–590. PubMed PMID: 29100011; PubMed Central PMCID: PMCPMC6039108.
   PubMed Web of Science ®Google Scholar
• Monaco L, Faccio L. Patient-driven search for rare disease therapies: the fondazione telethon success story and the strategy leading to strimvelis. EMBO Mol Med. 2017 Mar;9(3):289–292. PubMed PMID: 28148554; PubMed Central PMCID: PMCPMC5331198
   PubMed Web of Science ®Google Scholar
• Carbonaro DA, Zhang L, Jin X, et al. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. Mol Ther. 2014 Mar;22(3):607–622. PubMed PMID: 24256635; PubMed Central PMCID: PMCPMC3944341.
   PubMed Web of Science ®Google Scholar
• Eichler F, Duncan C, Musolino PL, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017 Oct 26;377(17):1630–1638. PubMed PMID: 28976817; PubMed Central PMCID: PMCPMC5708849.
   PubMed Web of Science ®Google Scholar
• Nayerossadat N, Maedeh T, Ali PA. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res. 2012;1:27. PubMed PMID: 23210086; PubMed Central PMCID: PMCPMC3507026
   PubMedGoogle Scholar
• Yamagata Y, Parietti V, Stockholm D, et al. Lentiviral transduction of CD34(+) cells induces genome-wide epigenetic modifications. PLoS One. 2012;7(11):e48943. PubMed PMID: 23145033; PubMed Central PMCID: PMCPMC3492239
   PubMed Web of Science ®Google Scholar
• Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther. 2005 Nov;16(11):1241–1246. PubMed PMID: 16259557
   PubMed Web of Science ®Google Scholar
• Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013 Aug 23;341(6148):1233158. PubMed PMID: 23845948.
   PubMed Web of Science ®Google Scholar
• Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet. 2016 Jul 30;388(10043):476–487. PubMed PMID: 27289174.
   PubMed Web of Science ®Google Scholar
• Huang J, Khan A, Au BC, et al. Lentivector iterations and pre-clinical scale-up/toxicity testing: targeting mobilized CD34(+) cells for correction of fabry disease. Mol Ther Methods Clin Dev. 2017 Jun;16(5):241–258. PubMed PMID: 28603745; PubMed Central PMCID: PMCPMC5453867.
   PubMed Web of Science ®Google Scholar
• Dunbar CE, Kohn DB, Schiffmann R, et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther. 1998 Nov 20;9(17):2629–2640. PubMed PMID: 9853529.
   PubMed Web of Science ®Google Scholar
• Dahl M, Doyle A, Olsson K, et al. Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. Mol Ther. 2015 May;23(5):835–844. PubMed PMID: 25655314; PubMed Central PMCID: PMCPMC4427872.
   PubMed Web of Science ®Google Scholar
• Harrison F, Yeagy BA, Rocca CJ, et al. Hematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis. Mol Ther. 2013 Feb;21(2):433–444. PubMed PMID: 23089735; PubMed Central PMCID: PMCPMC3594011.
   PubMed Web of Science ®Google Scholar
• Podetz-Pedersen KM, Karlen AD, Buckvold MP, et al. Prevention of neurocognitive deficit by ex vivo lentiviral transduction of hematopoietic stem cells in a murine model of mucopolysaccharidosis type II. Mol Ther. 2013;21:S191. 2013 May 01.
   Web of Science ®Google Scholar
• Sergijenko A, Langford-Smith A, Liao AY, et al. Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Mol Ther. 2013 Oct;21(10):1938–1949. PubMed PMID: 23748415; PubMed Central PMCID: PMCPMC3808137.
   PubMed Web of Science ®Google Scholar
• Holley RJ, Ellison SM, Fil D, et al. Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy. Brain. 2018 Jan 1;141(1):99–116. PubMed PMID: 29186350.
   PubMedGoogle Scholar
• Watts KL, Adair J, Kiem HP. Hematopoietic stem cell expansion and gene therapy. Cytotherapy. 2011 Nov;13(10):1164–1171. PubMed PMID: 21999373; PubMed Central PMCID: PMCPMC3291512
   PubMed Web of Science ®Google Scholar
• Carbonaro DA, Jin X, Petersen D, et al. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency. Mol Ther. 2006 Jun;13(6):1110–1120. PubMed PMID: 16651028.
   PubMed Web of Science ®Google Scholar
• Ahmed SS, Li J, Godwin J, et al. Gene transfer in the liver using recombinant adeno-associated virus. Curr Protoc Microbiol. 2013;Chapter 14:Unit14D 6. PubMed PMID: 23686826; PubMed Central PMCID: PMCPMC4161158
   PubMedGoogle Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011 Dec 22;365(25):2357–2365. PubMed PMID: 22149959; PubMed Central PMCID: PMCPMC3265081.
   PubMed Web of Science ®Google Scholar
• Zheng C, Baum BJ. Evaluation of promoters for use in tissue-specific gene delivery. Methods Mol Biol. 2008;434:205–219. PubMed PMID: 18470647; PubMed Central PMCID: PMCPMC2685069
   PubMedGoogle Scholar
• Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther. 2005 Aug;5(4):387–398. PubMed PMID: 16101513; PubMed Central PMCID: PMCPMC1368960
   PubMed Web of Science ®Google Scholar
• Sherman A, Schlachterman A, Cooper M, et al. Portal vein delivery of viral vectors for gene therapy for hemophilia. Methods Mol Biol. 2014;1114:413–426. PubMed PMID: 24557919; PubMed Central PMCID: PMCPMC4280906
   PubMedGoogle Scholar
• van Til NP, Markusic DM, van der Rijt R, et al. Kupffer cells and not liver sinusoidal endothelial cells prevent lentiviral transduction of hepatocytes. Mol Ther. 2005 Jan;11(1):26–34. PubMed PMID: 15585403.
   PubMed Web of Science ®Google Scholar
• Zincarelli C, Soltys S, Rengo G, et al. Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008 Jun;16(6):1073–1080. PubMed PMID: 18414476.
   PubMed Web of Science ®Google Scholar
• Bevan AK, Duque S, Foust KD, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther. 2011 Nov;19(11):1971–1980. PubMed PMID: 21811247; PubMed Central PMCID: PMCPMC3222525.
   PubMed Web of Science ®Google Scholar
• Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther. 2012 Apr;20(4):699–708. PubMed PMID: 22273577; PubMed Central PMCID: PMCPMC3321598
   PubMed Web of Science ®Google Scholar
• Smith BK, Collins SW, Conlon TJ, et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther. 2013 Jun;24(6):630–640. PubMed PMID: 23570273; PubMed Central PMCID: PMCPMC3689178.
   PubMed Web of Science ®Google Scholar
• Corti M, Cleaver B, Clement N, et al. Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in pompe disease: preclinical to clinical planning. Hum Gene Ther Clin Dev. 2015 Sep;26(3):185–193. PubMed PMID: 26390092; PubMed Central PMCID: PMCPMC4606909.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Hirai Y, Migita M, et al. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13777–13782. PubMed PMID: 12370426; PubMed Central PMCID: PMCPMC129774.
   PubMed Web of Science ®Google Scholar
• Zuckerman JN. The importance of injecting vaccines into muscle. Different patients need different needle sizes. BMJ. 2000 Nov 18;321(7271):1237–1238. PubMed PMID: 11082069; PubMed Central PMCID: PMCPMC1118997
   PubMedGoogle Scholar
• Horton HM, Anderson D, Hernandez P, et al. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1553–1558. PubMed PMID: 9990062; PubMed Central PMCID: PMCPMC15514
   PubMed Web of Science ®Google Scholar
• Kattenhorn LM, Tipper CH, Stoica L, et al. Adeno-associated virus gene therapy for liver disease. Hum Gene Ther. 2016 Dec;27(12):947–961. PubMed PMID: 27897038; PubMed Central PMCID: PMCPMC5177998.
   PubMed Web of Science ®Google Scholar
• Annoni A, Cantore A, Della Valle P, et al. Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. EMBO Mol Med. 2013 Nov;5(11):1684–1697. PubMed PMID: 24106222; PubMed Central PMCID: PMCPMC3840485.
   PubMed Web of Science ®Google Scholar
• Doerfler PA, Todd AG, Clement N, et al. Copackaged AAV9 vectors promote simultaneous immune tolerance and phenotypic correction of pompe disease. Hum Gene Ther. 2016 Jan;27(1):43–59. PubMed PMID: 26603344; PubMed Central PMCID: PMCPMC4741206.
   PubMed Web of Science ®Google Scholar
• Nietupski JB, Hurlbut GD, Ziegler RJ, et al. Systemic administration of AAV8-alpha-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression. Mol Ther. 2011 Nov;19(11):1999–2011. PubMed PMID: 21712814; PubMed Central PMCID: PMCPMC3222520.
   PubMed Web of Science ®Google Scholar
• Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood. 2007 Oct 1;110(7):2334–2341. PubMed PMID: 17609423; PubMed Central PMCID: PMCPMC1988950.
   PubMed Web of Science ®Google Scholar
• Wang G, Young SP, Bali D, et al. Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease. Mol Ther Methods Clin Dev. 2014;1:14018. PubMed PMID: 26015962; PubMed Central PMCID: PMCPMC4362383
   PubMed Web of Science ®Google Scholar
• Ferla R, Alliegro M, Marteau JB, et al. Non-clinical safety and efficacy of an AAV2/8 vector administered intravenously for treatment of mucopolysaccharidosis type VI. Mol Ther Methods Clin Dev. 2017 Sep;15(6):143–158. PubMed PMID: 28932756; PubMed Central PMCID: PMCPMC5552066.
   PubMed Web of Science ®Google Scholar
• Cotugno G, Annunziata P, Tessitore A, et al. Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer. Mol Ther. 2011 Mar;19(3):461–469. PubMed PMID: 21119624; PubMed Central PMCID: PMCPMC3048181.
   PubMed Web of Science ®Google Scholar
• Ferla R, O‘Malley T, Calcedo R, et al. Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8. Hum Gene Ther. 2013 Feb;24(2):163–169. PubMed PMID: 23194248; PubMed Central PMCID: PMCPMC3581049.
   PubMed Web of Science ®Google Scholar
• Ziegler RJ, Cherry M, Barbon CM, et al. Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A. Mol Ther. 2007 Mar;15(3):492–500. PubMed PMID: 17191071.
   Web of Science ®Google Scholar
• Choi JO, Lee MH, Park HY, et al. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer. J Biomed Sci. 2010 Apr;16(17):26. PubMed PMID: 20398385; PubMed Central PMCID: PMCPMC2861641.
   PubMed Web of Science ®Google Scholar
• Huston MW, Yasuda M, Pagant S, et al. Liver-based expression of the human alpha-galactosidase A gene in a murine Fabry model results in continuous therapeutic levels of enzyme activity and effective substrate reduction. Mol Genet Metab. 2018;123:2.
   Web of Science ®Google Scholar
• Ko AR, Jin DK, Cho SY, et al. AAV8-mediated expression of N-acetylglucosamine-1-phosphate transferase attenuates bone loss in a mouse model of mucolipidosis II. Mol Genet Metab. 2016 Apr;117(4):447–455. PubMed PMID: 26857995.
   PubMed Web of Science ®Google Scholar
• Hinderer C, Bell P, Gurda BL, et al. Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I. Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14894–14899. PubMed PMID: 25267637; PubMed Central PMCID: PMCPMC4205647.
   PubMed Web of Science ®Google Scholar
• Daya S, Cortez N, Berns KI. Adeno-associated virus site-specific integration is mediated by proteins of the nonhomologous end-joining pathway. J Virol. 2009 Nov;83(22):11655–11664. PubMed PMID: 19759155; PubMed Central PMCID: PMCPMC2772704
   PubMed Web of Science ®Google Scholar
• Wechsler T, DeKelver R, Laoharawee K, et al. ZFN-mediated in vivo genome editing of hepatocytes results in phenotypic correction in murine MPS I and MPS II models. Mol Genet Metab. 2018;123(2):S146–S147.
   Web of Science ®Google Scholar
• Pagant S, Huston MW, Yasuda M, et al. ZFN-mediated in vivo genome editing results in therapeutic levels of α-galactosidase A and effective substrate reduction in Fabry knockout mice. Mol Genet Metab. 2018;123:2.
   Web of Science ®Google Scholar
• Laoharawee K, DeKelver RC, Podetz-Pedersen KM, et al. Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing. Mol Ther. 2018 Apr 4;26(4):1127–1136. PubMed PMID: 29580682; PubMed Central PMCID: PMCPMC6080131.
   PubMed Web of Science ®Google Scholar
• Louis Jeune V, Joergensen JA, Hajjar RJ, et al. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods. 2013 Apr;24(2):59–67. PubMed PMID: 23442094; PubMed Central PMCID: PMCPMC3732124.
   PubMed Web of Science ®Google Scholar
• Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013 Jul 4;122(1):23–36. PubMed PMID: 23596044; PubMed Central PMCID: PMCPMC3701904.
   PubMed Web of Science ®Google Scholar
• Nault JC, Datta S, Imbeaud S, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015 Oct;47(10):1187–1193. PubMed PMID: 26301494.
   PubMed Web of Science ®Google Scholar
• Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 2001 Sep;8(17):1343–1346. PubMed PMID: 11571571.
   PubMed Web of Science ®Google Scholar
• Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018 Mar;29(3):285–298. PubMed PMID: 29378426; PubMed Central PMCID: PMCPMC5865262.
   PubMed Web of Science ®Google Scholar
• Li H, Malani N, Hamilton SR, et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood. 2011 Mar 24;117(12):3311–3319. PubMed PMID: 21106988; PubMed Central PMCID: PMCPMC3069673.
   PubMed Web of Science ®Google Scholar
• Cesana D, Ranzani M, Volpin M, et al. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther. 2014 Apr;22(4):774–785. PubMed PMID: 24441399; PubMed Central PMCID: PMCPMC3982501.
   PubMed Web of Science ®Google Scholar
• Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006 Jun;24(6):687–696. PubMed PMID: 16732270.
   PubMed Web of Science ®Google Scholar
• DePolo NJ, Reed JD, Sheridan PL, et al. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther. 2000 Sep;2(3):218–222. PubMed PMID: 10985952.
   PubMed Web of Science ®Google Scholar
• Fu H, Cataldi MP, Ware TA, et al. Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery. Mol Ther Methods Clin Dev. 2016;3:16036. PubMed PMID: 27331076; PubMed Central PMCID: PMCPMC4898406
   PubMed Web of Science ®Google Scholar
• Capotondo A, Milazzo R, Politi LS, et al. Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation. Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15018–15023. PubMed PMID: 22923692; PubMed Central PMCID: PMCPMC3443128.
   PubMed Web of Science ®Google Scholar
• Capotondo A, Milazzo R, Garcia-Manteiga JM, et al. Intracerebroventricular delivery of hematopoietic progenitors results in rapid and robust engraftment of microglia-like cells. Sci Adv. 2017 Dec;3(12):e1701211. PubMed PMID: 29226242; PubMed Central PMCID: PMCPMC5721728.
   PubMed Web of Science ®Google Scholar
• Sano R, Tessitore A, Ingrassia A, et al. Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology. Blood. 2005 Oct 1;106(7):2259–2268. PubMed PMID: 15941905; PubMed Central PMCID: PMCPMC1895262.
   PubMed Web of Science ®Google Scholar
• Futerman AH, van Meer G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol. 2004 Jul;5(7):554–565. PubMed PMID: 15232573
   PubMed Web of Science ®Google Scholar
• Gray SJ, Woodard KT, Samulski RJ. Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv. 2010 Oct;1(4):517–534. PubMed PMID: 22833965; PubMed Central PMCID: PMCPMC4509525
   PubMedGoogle Scholar
• Worgall S, Sondhi D, Hackett NR, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther. 2008 May;19(5):463–474. PubMed PMID: 18473686.
   PubMed Web of Science ®Google Scholar
• Tardieu M, Zerah M, Husson B, et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene Ther. 2014 Jun;25(6):506–516. PubMed PMID: 24524415.
   PubMed Web of Science ®Google Scholar
• Tardieu M, Zerah M, Gougeon ML, et al. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial. Lancet Neurol. 2017 Sep;16(9):712–720. PubMed PMID: 28713035.
   PubMed Web of Science ®Google Scholar
• Zerah M, Piguet F, Colle MA, et al. Intracerebral gene therapy using AAVrh.10-hARSA recombinant vector to treat patients with early-onset forms of metachromatic leukodystrophy: preclinical feasibility and safety assessments in nonhuman primates. Hum Gene Ther Clin Dev. 2015 Jun;26(2):113–124. PubMed PMID: 25758611.
   PubMed Web of Science ®Google Scholar
• Laoharawee K, Podetz-Pedersen KM, Nguyen TT, et al. Prevention of neurocognitive deficiency in mucopolysaccharidosis type II mice by central nervous system-directed, AAV9-mediated iduronate sulfatase gene transfer. Hum Gene Ther. 2017 Aug;28(8):626–638. PubMed PMID: 28478695.
   PubMed Web of Science ®Google Scholar
• Whiting RE, Jensen CA, Pearce JW, et al. Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease. Exp Eye Res. 2016 May;146:276–282. PubMed PMID: 27039708; PubMed Central PMCID: PMCPMC4957944.
   PubMed Web of Science ®Google Scholar
• Katz ML, Johnson GC, Leach SB, et al. Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression. Gene Ther. 2017 Apr;24(4):215–223. PubMed PMID: 28079862; PubMed Central PMCID: PMCPMC5398942.
   PubMed Web of Science ®Google Scholar
• Hughes MP, Smith DA, Morris L, et al. AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of niemann-pick type C1 disease. Hum Mol Genet. 2018 Sep 1;27(17):3079–3098. PubMed PMID: 29878115; PubMed Central PMCID: PMCPMC6097154.
   PubMed Web of Science ®Google Scholar
• McIntyre C, Derrick-Roberts AL, Byers S, et al. Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery. J Gene Med. 2014 Nov–Dec;16(11–12):374–387. PubMed PMID: 25418946.
   PubMed Web of Science ®Google Scholar
• Wolf DA, Lenander AW, Nan Z, et al. Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol Dis. 2011 Jul;43(1):123–133. PubMed PMID: 21397026; PubMed Central PMCID: PMCPMC4416491.
   PubMed Web of Science ®Google Scholar
• Rosenbloom BE, Weinreb NJ. Gaucher disease: a comprehensive review. Crit Rev Oncog. 2013;18(3):163–175. PubMed PMID: 23510062
   PubMedGoogle Scholar
• Haurigot V, Marco S, Ribera A, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest. 2013 Jul 1. DOI:10.1172/JCI66778. [ PubMed PMID: 23863627; PubMed Central PMCID: PMCPMC3726158].
   PubMed Web of Science ®Google Scholar
• Raben N, Fukuda T, Gilbert AL, et al. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther. 2005 Jan;11(1):48–56. PubMed PMID: 15585405.
   PubMed Web of Science ®Google Scholar
• Case LE, Beckemeyer AA, Kishnani PS. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations. Am J Med Genet C Semin Med Genet. 2012 Feb 15;160C(1):69–79. PubMed PMID: 22252989.
   PubMed Web of Science ®Google Scholar
• Maga JA, Zhou J, Kambampati R, et al. Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in pompe mice. J Biol Chem. 2013 Jan 18;288(3):1428–1438. PubMed PMID: 23188827; PubMed Central PMCID: PMCPMC3548456.
   PubMed Web of Science ®Google Scholar
• Byrne BJ, Geberhiwot T, Barshop BA, et al. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease. Orphanet J Rare Dis. 2017 Aug 24;12(1):144. PubMed PMID: 28838325; PubMed Central PMCID: PMCPMC5571484.
   PubMedGoogle Scholar
• Grubb JH, Vogler C, Sly WS. New strategies for enzyme replacement therapy for lysosomal storage diseases. Rejuvenation Res. 2010 Apr–Jun;13(2–3):229–236. PubMed PMID: 20345279; PubMed Central PMCID: PMCPMC2946059
   PubMed Web of Science ®Google Scholar
• Puzzo F, Colella P, Biferi MG, et al. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid alpha-glucosidase. Sci Transl Med. 2017 Nov 29;9(418). PubMed PMID: 29187643; PubMed Central PMCID: PMCPMC5826611. DOI:10.1126/scitranslmed.aam6375.
   PubMed Web of Science ®Google Scholar
• Sonoda H, Morimoto H, Yoden E, et al. A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol Ther. 2018 May 2;26(5):1366–1374. PubMed PMID: 29606503; PubMed Central PMCID: PMCPMC5993955.
   PubMed Web of Science ®Google Scholar
• Spencer BJ, Verma IM. Targeted delivery of proteins across the blood-brain barrier. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7594–7599. PubMed PMID: 17463083; PubMed Central PMCID: PMCPMC1857226.
   PubMed Web of Science ®Google Scholar
• Gleitz HF, Liao AY, Cook JR, et al. Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms. EMBO Mol Med. 2018 Jul;10(7). PubMed PMID: 29884617; PubMed Central PMCID: PMCPMC6034129. DOI:10.15252/emmm.201708730.
   PubMed Web of Science ®Google Scholar
• Sorrentino NC, D‘Orsi L, Sambri I, et al. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. EMBO Mol Med. 2013;May;5(5):675–690. PubMed PMID: 23568409; PubMed Central PMCID: PMCPMC3662312
   PubMed Web of Science ®Google Scholar
• Buning H, Huber A, Zhang L, et al. Engineering the AAV capsid to optimize vector-host-interactions. Curr Opin Pharmacol. 2015 Oct;24:94–104. PubMed PMID: 26302254.
   PubMed Web of Science ®Google Scholar
• Chen YH, Chang M, Davidson BL. Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med. 2009 Oct;15(10):1215–1218. PubMed PMID: 19749771; PubMed Central PMCID: PMCPMC3181494
   PubMed Web of Science ®Google Scholar
• Chen YH, Claflin K, Geoghegan JC, et al. Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol Ther. 2012 Jul;20(7):1393–1399. PubMed PMID: 22588273; PubMed Central PMCID: PMCPMC3392983.
   PubMed Web of Science ®Google Scholar
• Keeler AM, Zieger M, Todeasa SH, et al. Systemic delivery of AAVB1-GAA clears glycogen and prolongs survival in a mouse model of pompe disease. Hum Gene Ther. 2018 Jul 25. DOI:10.1089/hum.2018.016. [ PubMed PMID: 29901418].
   PubMed Web of Science ®Google Scholar
• Belur LR, Temme A, Podetz-Pedersen KM, et al. Intranasal adeno-associated virus mediated gene delivery and expression of human iduronidase in the central nervous system: a noninvasive and effective approach for prevention of neurologic disease in mucopolysaccharidosis type I. Hum Gene Ther. 2017 Jul;28(7):576–587. PubMed PMID: 28462595; PubMed Central PMCID: PMCPMC5549804.
   PubMed Web of Science ®Google Scholar
• Richter M, Saydaminova K, Yumul R, et al. In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors. Blood. 2016 Nov 3;128(18):2206–2217. PubMed PMID: 27554082; PubMed Central PMCID: PMCPMC5095755.
   PubMed Web of Science ®Google Scholar
• Nagree MS, Lopez-Vasquez L, Medin JA. Towards in vivo amplification: overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy. World J Stem Cells. 2015 Dec 26;7(11):1233–1250. PubMed PMID: 26730268; PubMed Central PMCID: PMCPMC4691692.
   PubMed Web of Science ®Google Scholar
• Wang H, Richter M, Psatha N, et al. A combined in vivo HSC transduction/selection approach results in efficient and stable gene expression in peripheral blood cells in mice. Mol Ther Methods Clin Dev. 2018 Mar;16(8):52–64. PubMed PMID: 29255741; PubMed Central PMCID: PMCPMC5722719.
   PubMed Web of Science ®Google Scholar
• Meneghini V, Frati G, Sala D, et al. Generation of human induced pluripotent stem cell-derived bona fide neural stem cells for ex vivo gene therapy of metachromatic leukodystrophy. Stem Cells Transl Med. 2017 Feb;6(2):352–368. PubMed PMID: 28191778; PubMed Central PMCID: PMCPMC5442804.
   PubMed Web of Science ®Google Scholar
• Selden NR, Al-Uzri A, Huhn SL, et al. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr. 2013 Jun;11(6):643–652. PubMed PMID: 23581634.
   PubMed Web of Science ®Google Scholar
• Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell. 2012 Jun 14;10(6):709–716. PubMed PMID: 22704511.
   PubMed Web of Science ®Google Scholar
• Nagree MS, Felizardo TC, Ahrenhoester CJ, et al. Abstract 374 – T rapa cells as vehicles for delivery of therapeutic cargo. Mol Ther. 2018;26(5, Supplement 1):1–459.
   PubMed Web of Science ®Google Scholar
• Fowler DH, Mossoba ME, Steinberg SM, et al. Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood. 2013 Apr 11;121(15):2864–2874. PubMed PMID: 23426943; PubMed Central PMCID: PMCPMC3624934.
   PubMed Web of Science ®Google Scholar
• Rafi MA, Rao HZ, Luzi P, et al. Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease. Mol Ther. 2012 Nov;20(11):2031–2042. PubMed PMID: 22850681; PubMed Central PMCID: PMCPMC3498799.
   PubMed Web of Science ®Google Scholar
• Bradbury AM, Rafi MA, Bagel JH, et al. AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (Krabbe disease). Hum Gene Ther. 2018 Jul;29(7):785–801. PubMed PMID: 29316812; PubMed Central PMCID: PMCPMC6066194.
   PubMed Web of Science ®Google Scholar
• Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010 Jun;21(6):704–712. PubMed PMID: 20095819.
   PubMed Web of Science ®Google Scholar
• Pien GC, Basner-Tschakarjan E, Hui DJ, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest. 2009 Jun;119(6):1688–1695. PubMed PMID: 19436115; PubMed Central PMCID: PMCPMC2689109.
   PubMed Web of Science ®Google Scholar
• Monteilhet V, Saheb S, Boutin S, et al. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther. 2011 Nov;19(11):2084–2091. PubMed PMID: 21629225; PubMed Central PMCID: PMCPMC3222518.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick Z, Leborgne C, Barbon E, et al. Influence of Pre-existing anti-capsid neutralizing and binding antibodies on AAV vector transduction. Mol Ther Methods Clin Dev. 2018 Jun;15(9):119–129. PubMed PMID: 29766022; PubMed Central PMCID: PMCPMC5948224.
   PubMed Web of Science ®Google Scholar
• Tse LV, Klinc KA, Madigan VJ, et al. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4812–E4821. PubMed PMID: 28559317; PubMed Central PMCID: PMCPMC5474820.
   PubMed Web of Science ®Google Scholar
• Meliani A, Boisgerault F, Hardet R, et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat Commun. 2018 Oct 5;9(1):4098. PubMed PMID: 30291246; PubMed Central PMCID: PMCPMC6173722.
   PubMedGoogle Scholar
• Sun B, Kulis MD, Young SP, et al. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther. 2010 Feb;18(2):353–360. PubMed PMID: 19690517; PubMed Central PMCID: PMCPMC2818301.
   PubMed Web of Science ®Google Scholar
• Sack BK, Herzog RW, Terhorst C, et al. Development of gene transfer for induction of antigen-specific tolerance. Mol Ther Methods Clin Dev. 2014 Apr;30(1):14013. PubMed PMID: 25558460; PubMed Central PMCID: PMCPMC4280786.
   PubMed Web of Science ®Google Scholar
• Clement N, Grieger JC. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev. 2016;3:16002. PubMed PMID: 27014711; PubMed Central PMCID: PMCPMC4804725
   PubMed Web of Science ®Google Scholar
• Talbot A, Nicholls K, Fletcher JM, et al. A simple method for quantification of plasma globotriaosylsphingosine: utility for Fabry disease. Mol Genet Metab. 2017 Sep;122(1–2):121–125. PubMed PMID: 28847675.
   PubMed Web of Science ®Google Scholar